Skip to Content

    Soliris, this biopharma company’s lucrative drug for rare blood disorders, helped infuse 24% sales growth in the second quarter of 2015.

    41319CFF-E47E-4BA5-B1B8-ECA4D480B0DFCreated with sketchtool.62900797-6A09-46DF-8323-A45758A81292Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

    Company Information

    Location
    Cheshire, CT
    Industry
    Pharmaceuticals
    Sector
    Health Care
    Fortune 500 Rank941
    Fortune 500 Profilehttp://fortune.com/fortune500/alexion-pharmaceuticals-941/
    Current Streak2
    Years on List4
    CEO
    David L. Hallal
    Websitehttp://www.alxn.com

    Revenue, Net Income

    Revenue Past Four Quarters2,267
    Net Income Past Four Quarters589

    Growth Rates

    EPS 3 yr Annual Growth Rate43%
    Rev 3 yr Annual Growth Rate40%
    Total Return 3 yr Annual Rate22%
    Beat S&P 3 yr Total Return?
    yes

    Rank

    EPS Growth Rank53
    Revenue Growth Rank25
    Total Return Rank
    86